Combine fluid pattern, choroidal and scleral anatomy, imaging and systemic context. Treatment and follow-up depend on the diagnosis; one percentage or waiting interval is insufficient.
Terminology and draft status
Terminology review is not complete. No new WHO UMD entry verification is claimed; pending entries and limits are recorded in terminology.md.
01Start with the fluid pattern and systemic context
Exudative retinal detachment without an obvious break is a finding, not a diagnosis. Assess the retina, retinal pigment epithelium (RPE), choroid and sclera; combine optical coherence tomography (OCT), fundus findings and selected angiography or ultrasound. BDUMP, UES, choroidal haemangioma and CSCR have different mechanisms and treatment pathways. 1
02Recognise BDUMP and investigate the associated tumour
Bilateral diffuse uveal melanocytic proliferation (BDUMP) is a rare paraneoplastic syndrome, distinct from direct metastasis into both eyes. A circulating tumour-related proliferative factor is a proposed mechanism. The original spindle-cell/no-mitosis/no-atypia description is a teaching pattern, not an absolute diagnostic rule; its “Hyperplasia-to-Neoplasia” label does not establish inevitable malignant transformation. 1
Red/brown fundus patches with early fluorescein-angiographic hyperfluorescence, rapidly progressive cataract, exudative detachment and diffuse choroidal thickening suggest the diagnosis; not every feature is mandatory. Lung cancer in men and ovarian cancer in women are classical associations, not an exclusive rule. The original mean-survival estimate of 12–15 months has no verified cohort denominator here and cannot predict an individual outcome. 1 6 7
Arrange prompt systemic oncology assessment and treatment of the underlying malignancy. Plasma exchange and steroids have been tried for ocular manifestations, but case reports cannot establish a cure or a survival benefit. In one report, a 67-year-old man with lung cancer improved anatomically and visually over 5 months during plasma exchange, radiation and chemotherapy; the effect of plasma exchange cannot be separated from the combined treatment. 6
Another report described a 54-year-old man with metastatic renal cancer receiving checkpoint inhibitors: bilateral melanocytic lesions, leopard-pattern FAF/FA, choroidal/ciliary thickening, subretinal fluid and bacillary layer detachment (BALAD) accompanied visual loss. Vision improved to 20/30 in both eyes at 7 months after plasma exchange. This is one selected case, not a standard protocol or proof of a uniform mechanism. 7
A 73-year-old man with metastatic ureter/urothelial carcinoma had no sustained improvement despite repeated plasma exchange. Successful and unsuccessful case reports have publication/selection bias and no controlled comparator; they cannot supply a numerical response rate or guarantee. 8
03Classify uveal effusion before selecting steroids or surgery
Uveal effusion syndrome (UES) requires assessment of scleral anatomy and exclusion of secondary inflammatory, neoplastic, hypotony-related, drug-related and postoperative causes. Glycosaminoglycan accumulation, scleral thickening, reduced permeability and impaired transscleral/venous drainage are proposed contributors; they are not one proven mechanism for every phenotype. 1 3
The traditional classification describes type 1 with nanophthalmos, type 2 with normal axial length but abnormal thick sclera, and type 3 with normal axial length and scleral thickness. The original <20 mm type -1 cutoff and “rarest” type -3 label are teaching claims, not universal definitions or frequency estimates. B-scan may show choroidal thickening and detachment. A T-sign can support posterior scleritis, but its absence does not exclude it; chronic leopard-spot RPE change is not specific to UES. 1 3
Shields 2017 retrospectively reviewed 104 eyes of 97 patients: 27 received oral steroids, 12 periocular steroids, 11 topical steroids and 54 observation. Only 59 eyes had follow-up: 21/12/6/20 in those groups. Effusion resolved in 56/59 (95%) and 3/59 (5%) required scleral windows. This denominator is neither all 104 eyes nor all patients treated with systemic steroids. 2
The selected discussion concerned non-nanophthalmic eyes without abnormal scleral thickening, corresponding to type 3. Baseline differences, heterogeneous treatment, missing follow-up and spontaneous resolution prevent a causal steroid-success conclusion; a lack of a clear resolution/recurrence difference between groups does not establish equivalence. No observed steroid-glaucoma is not zero risk, and cataract was reported in 9 eyes. 2
Scleral windows or subscleral sclerectomy are selected outflow procedures, not an obligatory step only after systemic-steroid failure in every type. Uyama 2000 reported a prospective noncomparative series of 19 eyes in 16 patients from 1989–1998, supporting a role for surgery in types 1/2. The series does not randomise medical versus surgical care; phenotype, symptoms and specialist assessment guide selection. 3
04Distinguish circumscribed and diffuse haemangioma
Choroidal haemangioma is a benign vascular hamartoma, requiring differentiation from melanoma and other masses. A circumscribed lesion is often rounded and orange-red; subretinal fluid reaching the macula may cause symptoms. Diffuse involvement is classically associated with Sturge–Weber syndrome and a “tomato-ketchup” fundus. Facial naevus flammeus in the relevant distribution warrants ocular risk assessment, including glaucoma and both fundi; not every unrelated skin birthmark has the same implication. 1
High internal A-scan reflectivity, an early lacy ICG pattern and Doppler flow are supporting observations, not universal diagnostic tests. Selected symptomatic exudative circumscribed lesions may be treated with photodynamic therapy (PDT) to reduce fluid and tumour height; diffuse disease needs a different plan. Anti-VEGF may address secondary exudation but is not a universal tumour cure. 1 4
Di Nicola 2020 retrospectively studied 79 consecutive PDT-treated patients and predictors of visual outcome. The inspected design/purpose excerpt does not supply a randomised comparator or establish a universal gold standard, a size cutoff or guaranteed vision preservation. Lesion size, initial vision, fluid and diagnosis guide counselling; complete outcome tables and confounding appraisal remain unavailable here. 4
| Method | Supporting finding |
|---|---|
| A-scan ultrasound | Often high internal reflectivity; not invariant or diagnostic alone. |
| ICG angiography | Early lacy/fenestrated pattern may support the diagnosis. |
| Colour Doppler | Flow within the lesion supports vascularity; velocity depends on acquisition. |
05Assess CSCR activity and review steroid exposure
Central serous chorioretinopathy (CSCR, also CRCS) belongs to the pachychoroid spectrum; choroidal hyperpermeability is important, but not every eye has identical thickness. Ask about stress, smoking and steroid exposure, including topical, systemic and inhaled treatment. These are risk/association histories, not proof of causation in the individual; not all exposure is abuse. Review necessary steroids with the prescriber and avoid abrupt withdrawal. 1
FA may show an inkstain or less often smokestack leak. OCT characterises the fluid and RPE; OCT angiography (OCT-A) helps assess type 1 macular/choroidal neovascularisation, which changes treatment. A negative OCT-A signal does not exclude every lesion; use selected FA/ICG and the full multimodal assessment when uncertainty persists. 1
The original 80–90% spontaneous-resolution estimate within 3–4 months is historical and population-dependent. Acute observation can be appropriate, but atypical findings, worsening vision, bilateral/occupational needs and suspected neovascularisation change the timing. Monitoring every 4–6 weeks and intervention after 3–6 months are teaching examples, not compulsory intervals for every patient. 1
PLACE 2018 randomised 179 patients with chronic CSCR to half-dose PDT (89) or high-density subthreshold micropulse laser (90). Complete subretinal-fluid resolution at 6–8 weeks was 51.2% versus 13.8%(P<0.001); persistent fluid allowed repeat assigned treatment. This is an anatomical primary endpoint. Later 7–8 month anatomy, acuity, microperimetry and quality of life are separate outcomes; the selected abstract access does not provide a complete bias/attrition or confidence-interval appraisal. 5
06Match follow-up and treatment to the confirmed diagnosis
For haemangioma, follow fluid, symptoms and lesion dimensions with appropriate imaging rather than height alone. For UES, scleral phenotype and exclusion of secondary causes guide observation, medical treatment or surgery; steroids are not a compulsory trial before all operations. For BDUMP, coordinate ocular monitoring with oncology rather than treating the eyes as isolated fluid collections. 1 2 3 4 6 7 8
Half-dose PDT and half-fluence PDT change different exposure components and are not interchangeable labels. Select a validated indication-specific protocol and actual product information; the PLACE comparison does not establish every reduced-setting regimen or a universal German national treatment rule. Avoid calling the synopsis guideline-certified when its original general DOG/BVA/S2k attribution has not been tied to an inspected current recommendation. 1 5
| Entity | Mechanism / context | Clinical clue | Selected treatment | Limits / precautions |
|---|---|---|---|---|
| BDUMP | Paraneoplastic proliferation; malignant transformation not established | Red patches, early cataract, exudative detachment | Treat underlying tumour; selected plasma exchange | No-mitosis teaching pattern is not an absolute exclusion rule; investigate occult malignancy promptly. |
| UES | Scleral outflow factors; phenotype matters | Type 1 teaching AL<20 mm; leopard-spot RPE | Selected observation/steroids or scleral windows | 95% means 56/59 followed eyes in a mixed retrospective series; T-sign absence does not exclude posterior scleritis. |
| Haemangioma | Benign vascular hamartoma | Orange-red lesion and often high A-scan reflectivity | PDT for selected symptomatic exudative circumscribed lesions | Di Nicola 2020 retrospective study is not universal superiority proof; assess Sturge–Weber-associated glaucoma/fundus risk. |
| CSCR | Pachychoroid/hyperpermeability | FA inkstain/smokestack; review steroid and stress history | Selected observation; half-dose PDT for suitable persistent disease | 3–6 month teaching interval is not mandatory; do not abruptly stop essential steroids; negative OCT-A does not exclude all CNV. |
What are the main learning points?
Combine fluid pattern, choroidal and scleral anatomy, imaging and systemic context. Treatment and follow-up depend on the diagnosis; one percentage or waiting interval is insufficient.
When is assessment urgent?
Sudden visual loss, new field loss, severe pain, marked inflammation, pressure rise or suspected infection needs urgent assessment. Suspected BDUMP requires prompt ophthalmic and systemic oncology evaluation.
References and access status
- 1Immutable original export; own full choroidal-disease export
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
- 2Shields 2017 UES outcomes; PMID 29133632
Full indexed primary abstract and selected PMC discussion/conclusion read 17 November 2026; not full tables, figures or report.
- 3Uyama 2000 UES subscleral sclerectomy; PMID 10711879
Selected primary abstract purpose/design/conclusion excerpts read 17 November 2026; complete methods/results and subtype tables unread.
- 4Di Nicola 2020 PDT for circumscribed haemangioma; PMID 32344158
Indexed title/design/purpose and selected excerpt read 17 November 2026; not complete abstract/report. Retrospective 79 patients.
- 5PLACE 2018 chronic CSCR randomised trial; PMID 29776672
Selected indexed primary abstract methods/results read 17 November 2026; full paper/protocol/supplement, masking/attrition and CI appraisal remain open.
- 6BDUMP lung-cancer combined-treatment case; PMID 25383840
Complete indexed primary abstract read 17 November 2026; full case/figures/protocol unread. Single combined-treatment observation.
- 7BDUMP renal-cancer/checkpoint-inhibitor case; PMID 35243136
Complete indexed primary abstract and selected PMC discussion excerpt read 17 November 2026; full case/figures unread. Single observation, no guarantee.
- 8BDUMP urothelial-cancer failed-response case; PMID 35724372
Complete indexed primary abstract read 17 November 2026; full case/figures unread. No sustained plasma-exchange response.
Original lecture link
For patients
Fluid beneath the retina has several possible causes. Eye examination and selected imaging distinguish them; some findings also require investigation for disease elsewhere in the body.
Examination and selected tests guide individual treatment and follow-up; this educational text cannot replace your own assessment.
Sudden visual loss, new field loss, severe pain, marked inflammation, pressure rise or suspected infection needs urgent assessment. Suspected BDUMP requires prompt ophthalmic and systemic oncology evaluation.
Sudden visual loss, new field loss, severe pain, marked inflammation, pressure rise or suspected infection needs urgent assessment. Suspected BDUMP requires prompt ophthalmic and systemic oncology evaluation.